TMDX
NasdaqTransMedics Group, Inc.
Technology · Electromedical & Electrotherapeutic Apparatus
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$30.3M
2021
$93.5M
2022
$241.6M
2023
$441.5M
2024
$605.5M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$605.5M
Net Income$190.3M
Gross Profit$362.8M
Oper Income$108.6M
EPS (dil)$4.87
Rev/sh$17.52
FCF/sh$3.87
Book/sh$13.69
Gross M59.9%
Oper M17.9%
Profit M31.4%
FCF M22.1%
ROE40.2%
ROA17.8%
ROIC362.4%
R&D/Rev11.4%
Rev Y/Y37.1%
Rev 3Y CAGR86.4%
EPS Y/Y382.2%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh$0.00
Shs Chg Y/Y+15.1%
Current Ratio7.14
Quick Ratio6.59
Debt/Eq0.15
Int Coverage7.9×
Net Debt$420.1M cash
Total Debt$68.8M
Cash & Eq$488.9M
Total Assets$1.1B
Oper CF$192.8M
Capex$59.3M
Free CF$133.6M
Buybacks—
Equity$473.1M
Liabilities$595.3M
Shs Outstand0.03B
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $30.3M | $93.5M | $241.6M | $441.5M | $605.5M |
| Gross Profit | $21.2M | $65.3M | $154.1M | $262.1M | $362.8M |
| Operating Income | $-39.4M | $-31.4M | $-28.7M | $37.5M | $108.6M |
| Net Income | $-44.2M | $-36.2M | $-25.0M | $35.5M | $190.3M |
| Diluted EPS | $-1.60 | $-1.23 | $-0.77 | $1.01 | $4.87 |
| Operating Cash Flow | $-28.9M | $-45.8M | $-13.0M | $48.8M | $192.8M |
| Free Cash Flow | $-32.4M | $-57.7M | $-164.9M | $-80.9M | $133.6M |
COMMUNITY · $TMDX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.